SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and Drug Admini ...

SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of two additional clinical trial sites for its ongoing Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer’s disease (“AD”) ...

New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes. SANTA ANA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeu ...

SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced an upcoming presentation on Phase 1 clinical data from the Company's Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer's disease (AD), at ...

Moderate Alzheimer’s disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment. After 12 months of treatment, both patients who completed 17 doses improved from moderate to mild AD within just 3 months. One patient stabilized at their improved score, while the other patient continued to show ongoing improvement. Clinical development of troculeucel is ongoing and will be evaluated for safety and efficacy in the randomized, placebo-controlled Phase 2a ...

Core Viewpoint - NKGen Biotech has initiated the administration of troculeucel, an autologous NK cell therapy, to a stroke patient under a compassionate use IND approved by the FDA, marking a significant step in exploring its therapeutic potential in post-stroke treatment [1][3]. Company Overview - NKGen Biotech is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous and allogeneic NK cell therapeutics, headquartered in Santa Ana, California [7]. Product Development - Troculeucel is a novel, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate, being developed for neurodegenerative disorders and various cancers. The WHO has assigned the International Nonproprietary Name (INN) "troculeucel" for SNK01, which is a significant milestone for the company [6]. Clinical Collaboration - NKGen is collaborating with Dr. Dimitri Sigounas and Dr. Amarendra K. Neppalli from George Washington University Medical Center to explore the potential of troculeucel in reducing chronic neuroinflammation and damage in stroke patients [3][5]. Clinical Assessment - The stroke patient receiving troculeucel will undergo regular independent assessments by Dr. Sigounas at GWU Medical Center to evaluate the treatment's effectiveness [4]. Research Insights - Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are identified as markers of brain injury, and previous trials have shown that troculeucel can cross the blood-brain barrier to reduce cerebrospinal fluid levels of these markers, indicating its potential to improve outcomes in stroke patients [5].